- Home
- DMAC vs GDC Comparison
DMAC vs GDC Comparison
Compare DMAC & GDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- GDC
- Stock Information
- Founded
- DMAC 2000
- GDC 2015
- Country
- DMAC United States
- GDC United States
- Employees
- DMAC N/A
- GDC N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- GDC Steel/Iron Ore
- Sector
- DMAC Health Care
- GDC Industrials
- Exchange
- DMAC Nasdaq
- GDC Nasdaq
- Market Cap
- DMAC 310.1M
- GDC 342.6M
- IPO Year
- DMAC N/A
- GDC N/A
- Fundamental
- Price
- DMAC $6.70
- GDC $4.29
- Analyst Decision
- DMAC Strong Buy
- GDC
- Analyst Count
- DMAC 3
- GDC 0
- Target Price
- DMAC $12.33
- GDC N/A
- AVG Volume (30 Days)
- DMAC 256.1K
- GDC 100.2K
- Earning Date
- DMAC 11-12-2025
- GDC 11-13-2025
- Dividend Yield
- DMAC N/A
- GDC N/A
- EPS Growth
- DMAC N/A
- GDC N/A
- EPS
- DMAC N/A
- GDC N/A
- Revenue
- DMAC N/A
- GDC N/A
- Revenue This Year
- DMAC N/A
- GDC N/A
- Revenue Next Year
- DMAC N/A
- GDC N/A
- P/E Ratio
- DMAC N/A
- GDC N/A
- Revenue Growth
- DMAC N/A
- GDC N/A
- 52 Week Low
- DMAC $3.19
- GDC $1.03
- 52 Week High
- DMAC $7.49
- GDC $9.92
- Technical
- Relative Strength Index (RSI)
- DMAC 48.84
- GDC 39.94
- Support Level
- DMAC $6.50
- GDC $3.95
- Resistance Level
- DMAC $7.10
- GDC $4.80
- Average True Range (ATR)
- DMAC 0.29
- GDC 0.45
- MACD
- DMAC -0.03
- GDC -0.13
- Stochastic Oscillator
- DMAC 32.90
- GDC 6.35
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About GDC GD Culture Group Limited
GD Culture Group Ltd focuses its business on two segments mainly through the Company and two subsidiaries. 1) AI-driven digital human creation and customization; 2) Live streaming and e-commerce. The company has relentlessly been focusing on serving its customers and creating value for them through the continual innovation and optimization of its products and services. For the AI-driven digital human creation and customization sector, the Company uses AI algorithms and software to generate realistic 3D or 2D digital human models. AI algorithms and machine learning models are used to simulate human characteristics, such as facial expressions, body movements, and even speech patterns.